SGMT | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 19%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.22%

1 Month

5.33%

3 Months

-12.64%

6 Months

-21.45%

1 Year

62.89%

2 Year

0.91%

Key data

Stock price

$5.53

P/E Ratio

0.00

DAY RANGE

$5.38 - $5.66

EPS

-$1.73

52 WEEK RANGE

$1.73 - $11.41

52 WEEK CHANGE

$57.55

MARKET CAP

223.098 M

YIELD

N/A

SHARES OUTSTANDING

32.522 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-14-2025

BETA

2.59

PUBLIC FLOAT

AVERAGE 10 VOLUME

$292,430

AVERAGE 30 VOLUME

$441,650

Company detail

CEO: David Happel
Region: US
Website: www.sagimet.com
Employees: 0
IPO year: 2023

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. We were incorporated in Delaware in December 2006 under the name 3-V Biosciences, Inc., and changed our name to Sagimet Biosciences Inc. in August 2019. Our principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California.

SGMT - Sagimet Biosciences Inc.